Alvotech SA
NASDAQ:ALVO
Intrinsic Value
Alvotech SA is a LU-based company operating in Biotechnology industry. [ Read More ]
The intrinsic value of one ALVO stock under the Base Case scenario is 19.412 USD. Compared to the current market price of 13.335 USD, Alvotech SA is Undervalued by 31%.
Valuation Backtest
Alvotech SA
Run backtest to discover the historical profit from buying and selling ALVO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Alvotech SA
Current Assets | 194.8m |
Cash & Short-Term Investments | 11.2m |
Receivables | 87.2m |
Other Current Assets | 96.5m |
Non-Current Assets | 755.2m |
Long-Term Investments | 18.5m |
PP&E | 356.6m |
Intangibles | 31.1m |
Other Non-Current Assets | 349m |
Current Liabilities | 261m |
Accounts Payable | 80.6m |
Accrued Liabilities | 62.7m |
Other Current Liabilities | 117.7m |
Non-Current Liabilities | 1.6B |
Long-Term Debt | 1B |
Other Non-Current Liabilities | 593.9m |
Earnings Waterfall
Alvotech SA
Revenue
|
93.4m
USD
|
Cost of Revenue
|
-160.9m
USD
|
Gross Profit
|
-67.5m
USD
|
Operating Expenses
|
-287.4m
USD
|
Operating Income
|
-354.9m
USD
|
Other Expenses
|
-196.9m
USD
|
Net Income
|
-551.7m
USD
|
Free Cash Flow Analysis
Alvotech SA
ALVO Profitability Score
Profitability Due Diligence
Alvotech SA's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Alvotech SA's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
ALVO Solvency Score
Solvency Due Diligence
Alvotech SA's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Score
Alvotech SA's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALVO Price Targets Summary
Alvotech SA
According to Wall Street analysts, the average 1-year price target for ALVO is 16.83 USD with a low forecast of 6.06 USD and a high forecast of 29.4 USD.
Shareholder Return
ALVO Price
Alvotech SA
Average Annual Return | 5.04% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -51% |
Market Capitalization | 3.6B USD |
Shares Outstanding | 279 567 008 |
Percentage of Shares Shorted | 0.27% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alvotech SA is a LU-based company operating in Biotechnology industry. Alvotech SA is a biotechnology company. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Contact
IPO
Employees
Officers
The intrinsic value of one ALVO stock under the Base Case scenario is 19.412 USD.
Compared to the current market price of 13.335 USD, Alvotech SA is Undervalued by 31%.